NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free CTKB Stock Alerts $5.66 -0.15 (-2.58%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.65▼$5.8150-Day Range$5.80▼$9.1552-Week Range$3.80▼$12.31Volume477,762 shsAverage Volume733,212 shsMarket Capitalization$740.44 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cytek Biosciences alerts: Email Address Cytek Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside57.3% Upside$9.00 Price TargetShort InterestBearish8.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 5 Articles This WeekInsider TradingSelling Shares$266,100 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.04) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.87 out of 5 starsMedical Sector738th out of 909 stocksAnalytical Instruments Industry23rd out of 27 stocks 3.3 Analyst's Opinion Consensus RatingCytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytek Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.35% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 16.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTKB. Previous Next 3.0 News and Social Media Coverage News SentimentCytek Biosciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for CTKB on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $266,100.00 in company stock.Percentage Held by Insiders15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.04) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -63.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -63.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Cytek Biosciences Stock (NASDAQ:CTKB)Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More CTKB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTKB Stock News HeadlinesApril 24, 2024 | insidertrades.comMing Yan Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) StockApril 13, 2024 | insidertrades.comMing Yan Sells 1,900 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) StockApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 24, 2024 | americanbankingnews.comCytek Biosciences, Inc. (NASDAQ:CTKB) CTO Ming Yan Sells 20,000 Shares of StockMarch 27, 2024 | investorplace.comCTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023March 21, 2024 | markets.businessinsider.comOptimistic Outlook: Cytek Biosciences Poised for Growth with New CFO AppointmentMarch 20, 2024 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc's (CTKB) Chief Technology Officer Ming Yan Sells 40,000 SharesMarch 19, 2024 | markets.businessinsider.comCytek Biosciences Names William McCombe To Succeed Patrik Jeanmonod As CFO; Reaffirms 2024 OutlookApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 19, 2024 | globenewswire.comCytek® Biosciences Names William McCombe Chief Financial OfficerMarch 15, 2024 | finance.yahoo.comCTKB Mar 2024 5.000 putMarch 7, 2024 | globenewswire.comCytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis SolutionsMarch 7, 2024 | finanznachrichten.deCytek Biosciences, Inc.: Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 OutlookMarch 6, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)March 1, 2024 | seekingalpha.comCytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | investing.comCytek Biosciences earnings matched, revenue topped estimatesMarch 1, 2024 | finance.yahoo.comCytek Biosciences Reports Full Year 2023 EarningsMarch 1, 2024 | finance.yahoo.comCytek Biosciences Inc (CTKB) Reports Robust Revenue Growth and Positive Net Income in Q4 2023February 29, 2024 | finance.yahoo.comCytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | globenewswire.comCytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 OutlookFebruary 13, 2024 | finance.yahoo.comAfter losing 27% in the past year, Cytek Biosciences, Inc. (NASDAQ:CTKB) institutional owners must be relieved by the recent gainJanuary 17, 2024 | finance.yahoo.comCytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific DiscoveriesJanuary 8, 2024 | finance.yahoo.comCytek Biosciences Announces Preliminary Full Year 2023 Revenue ResultsDecember 28, 2023 | finance.yahoo.comCytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 22, 2023 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 SharesDecember 19, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)December 14, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Cytek BiosciencesSee More Headlines Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees676Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+54.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,150,000.00 Net Margins-6.29% Pretax Margin-8.14% Return on Equity-1.40% Return on Assets-1.13% Debt Debt-to-Equity RatioN/A Current Ratio6.97 Quick Ratio5.89 Sales & Book Value Annual Sales$193.01 million Price / Sales3.94 Cash Flow$0.03 per share Price / Cash Flow229.95 Book Value$2.90 per share Price / Book2.00Miscellaneous Outstanding Shares130,820,000Free Float110,023,000Market Cap$760.06 million OptionableOptionable Beta1.37 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Wenbin Jiang Ph.D. (Age 60)President, CEO & Chairman of the Board Comp: $964.21kDr. Ming Yan Ph.D. (Age 61)CTO & Director Comp: $616.26kMs. Valerie T. Barnett J.D. (Age 48)Chief Legal Officer Comp: $535.98kMr. William D. McCombe (Age 66)Chief Financial Officer Mr. Chris Williams (Age 55)Chief Operating Officer Dr. Allen B. Poirson Ph.D. (Age 64)Senior Vice President of Business & Corporate Development Dr. Philippe Busque Ph.D.Senior Vice President of Global Sales & ServicesMr. Patrik Sebastian Jeanmonod (Age 57)Head of Corporate Development Analytics Comp: $412.54kMore ExecutivesKey CompetitorsStandard BioToolsNASDAQ:LABEyePoint PharmaceuticalsNASDAQ:EYPTQuanterixNASDAQ:QTRXAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNView All CompetitorsInsiders & InstitutionsMing YanSold 20,000 sharesTotal: $117,400.00 ($5.87/share)Ming YanSold 1,900 sharesTotal: $13,300.00 ($7.00/share)PNC Financial Services Group Inc.Sold 2,267 shares on 3/22/2024Ownership: 0.005%Ming YanSold 20,000 sharesTotal: $135,400.00 ($6.77/share)Vanguard Group Inc.Bought 811,279 shares on 3/11/2024Ownership: 8.772%View All Insider TransactionsView All Institutional Transactions CTKB Stock Analysis - Frequently Asked Questions Should I buy or sell Cytek Biosciences stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks. What is Cytek Biosciences' stock price target for 2024? 5 brokers have issued 1-year price objectives for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts. How have CTKB shares performed in 2024? Cytek Biosciences' stock was trading at $9.12 at the beginning of the year. Since then, CTKB shares have decreased by 37.3% and is now trading at $5.72. View the best growth stocks for 2024 here. Are investors shorting Cytek Biosciences? Cytek Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,950,000 shares, an increase of 16.9% from the March 15th total of 8,510,000 shares. Based on an average daily trading volume, of 723,300 shares, the short-interest ratio is presently 13.8 days. Currently, 8.4% of the shares of the company are sold short. View Cytek Biosciences' Short Interest. When is Cytek Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CTKB earnings forecast. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) posted its quarterly earnings data on Wednesday, March, 13th. The company reported $0.04 EPS for the quarter. The business earned $58.23 million during the quarter, compared to the consensus estimate of $56.66 million. Cytek Biosciences had a negative net margin of 6.29% and a negative trailing twelve-month return on equity of 1.40%. What ETF holds Cytek Biosciences' stock? First Trust Nasdaq Lux Digital Health Solutions ETF holds 1,294 shares of CTKB stock, representing 0.33% of its portfolio. What guidance has Cytek Biosciences issued on next quarter's earnings? Cytek Biosciences updated its FY 2024 earnings guidance on Thursday, April, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.9 million. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTKB) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
